Skip to main content
HERON THERAPEUTICS, INC. /DE/ logo

HERON THERAPEUTICS, INC. /DE/ — Investor Relations & Filings

Ticker · HRTX ISIN · US4277461020 LEI · 549300DR2I1DOPD2IX53 US Manufacturing
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2025-06-10 Director's Dealing
Country US United States of America
Listing US HRTX

About HERON THERAPEUTICS, INC. /DE/

https://www.herontx.com/

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology. The company utilizes its proprietary drug delivery technologies to create novel, best-in-class treatments. Its product portfolio is designed to improve the lives of patients by providing solutions for significant medical issues, including postoperative pain management, with an aim to reduce opioid reliance, as well as managing postoperative and chemotherapy-induced nausea and vomiting.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-06-10 English
4
Director's Dealing
2025-05-07 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about stock options and restricted stock units granted as inducement awards. The document references incorporation of other filings such as the Annual Report on Form 10-K and Quarterly Report on Form 10-Q but itself is a registration statement for securities issuance, not a financial report or earnings release. It is not an announcement of a report but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-05-06 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2025, by Heron Therapeutics, Inc. It specifically references the issuance of a press release announcing financial results for the quarter ended March 31, 2025. The document states that the press release is furnished as an exhibit and is intended to be furnished, not filed, indicating it is an earnings release announcement rather than a full financial report. The document length is 3589 characters, which is relatively short and consistent with an earnings release filing rather than a comprehensive report. The key section is Item 2.02, which is typically used for earnings releases or financial results announcements. Therefore, the document is best classified as an Earnings Release (ER).
2025-05-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates the filing is about a press release announcing a settlement agreement related to patent litigation. There are no financial statements or detailed financial data included, only a reference to a press release as an exhibit. The document length is 3346 characters, which is relatively short and consistent with an announcement rather than a full report. The content does not fit categories like Annual Report, Earnings Release, or Management Reports. It is primarily a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-05-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.